Skip to main content
Equibles
ASTH logo

ASTH · Astrana Health, Inc. · Metrics

Track ASTH — free

Use ASTH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ASTH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$38.16 +0.15 (+0.39%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.11B
Shares
55.74M
Volume · Oct 23 3126 Avg daily vol (3M) 421.78K

ASTH metrics

109 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$38.01
Market cap
$2.11B

Price action

20 metrics
Price change (1W)
-0.1%
Price change (30D)
+8.3%
Price change (3M)
-7.3%
Price change (6M)
+15.4%
Price change (YTD)
+53.2%
Price change (1Y)
+14.8%
Trailing year
Price change (5Y)
-47.2%
52-week high
$49.81
52-week low
$18.16
Change from 52-week high
-23.7%
Change from 52-week low
+109.3%
Annualized volatility
67.1%
Annualized volatility (3M)
50.2%
Beta
0.6
RSI (14D)
54.0
Price vs SMA 50
+1.7%
Price vs SMA 200
+13.2%
Avg volume (3M)
421,784
Relative volume
0.5
Average dollar volume
$15.58M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
55.74M

Valuation

12 metrics
P / E (TTM)
46.4
Trailing earnings · reciprocal yield 2.2%
PEG ratio
0.4
EV / revenue
0.7×
reciprocal yield 145.5%
EV / EBITDA
16.2×
reciprocal yield 6.2%
EV / EBIT
26.3×
reciprocal yield 3.8%
P / sales
0.5×
reciprocal yield 182.5%
P / book
2.5
reciprocal yield 39.4%
FCF yield
4.5%
TTM · current market cap
Buyback yield
0.8%
P / FCF
22.3
reciprocal yield 4.5%
P / operating cash flow
19.5
reciprocal yield 5.1%
Earnings yield
1.9%

Historical valuation

8 metrics
P / E historical average (3Y)
45.9×
reciprocal yield 2.2%
P / E historical average (5Y)
42.4×
reciprocal yield 2.4%
EV / revenue historical average (3Y)
1.1×
reciprocal yield 94.1%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 62.5%
EV / EBIT historical average (3Y)
25.2×
reciprocal yield 4.0%
EV / EBIT historical average (5Y)
24.7×
reciprocal yield 4.0%
EV / EBITDA historical average (3Y)
18.4×
reciprocal yield 5.4%
EV / EBITDA historical average (5Y)
19.1×
reciprocal yield 5.2%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
4.6%
Shareholder yield
0.9%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
2.6%
Trailing 12 months
Net margin
1.1%
Gross profit (TTM)
$147.97M
Operating profit (TTM)
$100.45M
Net income (TTM)
$40.55M
Trailing 12 months
Diluted EPS (TTM)
$0.82
FCF margin
2.5%
Effective tax rate
34.7%

Per share

11 metrics
Revenue per diluted share (TTM)
$77.67
Gross profit per diluted share (TTM)
$3.95
Operating profit per diluted share (TTM)
$2.03
EBITDA per diluted share (TTM)
$3.30
Net income per diluted share (TTM)
$0.82
Operating cash flow per diluted share (TTM)
$2.19
Free cash flow per diluted share (TTM)
$1.92
Capital expenditures per diluted share (TTM)
$0.27
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.82
Book value per share
$15.94

Growth

11 metrics
Revenue growth YoY
+48.5%
Year over year
Net income growth YoY
+109.5%
Revenue (TTM)
$3.84B
Trailing 12 months
EPS growth YoY
+110.5%
Shares change YoY
+0.6%
Year over year · more shares
Revenue CAGR (3Y)
+40.6%
Revenue CAGR (5Y)
+35.9%
EPS CAGR (3Y)
-22.5%
EPS CAGR (5Y)
-14.6%
FCF CAGR (3Y)
+20.9%
FCF CAGR (5Y)
+18.4%

Quality

14 metrics
Return on equity
4.9%
Return on assets
1.8%
Debt / equity
1.1
Current ratio
1.2
EBITDA (TTM)
$163.48M
Free cash flow (TTM)
$94.38M
Quick ratio
1.2
Interest coverage
1.5
Net debt / EBITDA
3.3
Return on invested capital
4.8%
Trailing 12 months
Net cash
−$535.71M
Latest balance sheet
Cash & equivalents
$400.79M
Total assets
$2.28B
Total debt
$936.50M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$107.87M
Capital expenditures (TTM)
$13.49M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$40.76M
R&D / revenue
—
Stock compensation / revenue
1.1%

Ownership (13F)

9 metrics
13F filers
211
13F filer change QoQ
+40
Institutional ownership
57.9%
Conviction holders (share of 13F filers)
1.0%
Crowding (high-turnover and private-fund holders)
12.2%
Private-fund adviser ownership
11.9%
Active holders' share change QoQ
+4.2%
Holder tenure
13.0
Price vs estimated holder cost
+34.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
22.6%

Short interest

3 metrics
Short interest
5.5%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1083446 CUSIP 03763A207 13F (30d) 27 filings 27 filers Visit website Investor relations